Fig. 3. AB23Ac inhibits OVA-induced immune cell accumulation in BALF. (A) Mice were sensitized with OVA twice by i.p. injection on D0 and D14 and were subsequently challenged on D28, D29, and D30 with nebulized OVA. AB23Ac was administrated intraperitoneally at a dose of 60 mg/kg 30 min before the OVA sensitization or before the OVA challenge. The cells in the BALF were stained using May-Grünwald stain and counted. (B) Total cell counts, eosinophils, and macrophages in the BALF. (C) Lymphocyte counts in BALF. The results are presented as means ± the SEM cell count values (n=5). *p<0.05, **p<0.01, ***p<0.001 vs. the PBS-treated group, #p<0.05, ##p<0.01 vs. the OVA-treated group.
© Biomolecules & Therapeutics
